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Introduction: Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in 
children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase 
inhibitors (TKI), the frequency of accelerated phase (AP) or blast crisis (BC) is remarkably reduced, 
estimated to 1% to 1.5% per year in adults compared with more than 20% per year in the pre-TKI 
era. But no data are available among children.  
Purpose: We described the characteristics, the treatment and the outcome of 21 children with 
CML, who evolved in accelerated phase and/or blast crisis under TKI.  
Results: From 2001 to april 2015, 415 European patients were enrolled in the CML pediatric 
database. Twenty-one patients (5.1%), in chronic phase (CP) treated by TKI, presented AP or BC. 
The median age of AP /BC cohort was 13.2 years (range: 4.5-16.9 years) with a sex ratio M/F at 
2. At CML diagnosis, 15 patients (71%) had high risk Sokal Score with a median score of 1,4 
(range: 0,16-2,4). All patients harbored t(9;22)(q34;q11) but one had a complex translocation 
t(1;9;22)(q12;q34;q11) and another one presented additional inv(3)(q21q26). Imatinib was the 
first line TKI for all patients. Before AP or BC, only five patients (24%) obtained a complete 
cytogenetic response (CCyR) and three achieved MMR. For incomplete molecular response or 
progression to accelerated phase, 8 patients (38%) were switched to dasatinib. Median duration of 
TKI before AP or BC was 11 months (range: 3 months-56.5 months). Six patients evolved to AP 
with a median interval of 8.7 months (range: 1 months-24 months), leading to blast crisis for 4 
patients with a median time of 3.5 months (range: 0.3-5.4 months). Among the 2 patients 
remaining in AP, imatinib was increased for one and the other was switched for dasatinib, all 
before hematopoietic stem cells transplantation (HSCT). One patient died of post-transplant 
complication and the other one is still alive in complete molecular response without TKI. Nineteen 
patients presented BC, including 4 after AP. Thirteen patients (62%) presented ALL, five (24%) AML 
and one a bi phenotypic leukemia. Central nervous system (CNS) was involved for two patients 
with ALL, one isolated, one combined. At AP or BC, nine patients (43%) presented new additional 
cytogenetic abnormalities. Eighteen patients with BC were treated according to AML or ALL 
protocols, combined with second generation TKI for twelve patients. Only one patient underwent 
preparative regimen, without intensive chemotherapy before HSCT. Ten patients reached 
complete remission. Four patients died before HSCT, by progressive disease for 2 and by fatal 
infection for 2. Overall, 15 patients in BC were transplanted. Before HSCT, median molecular 
response was 0.2% (range: 0-29%) and only four patients had a complete molecular response. 
After transplant, seven patients received second generation TKI. Four patients died, including 
three related to transplant toxicity. Thirteen patients were alive, but one with ALL BC relapsed 26 
months post-transplant and was waiting for second HSCT. With a median follow-up of 4.4 years, 
4-year overall survival was 59% (66% for ALL BC versus 40% for AML BC).  
Conclusion: Incidence of AP/BC after imatinib for CP CML is at 5%, in the CML pediatric database. 
Despite second generation TKI, combined with HSCT, outcome remains poor. Post-transplant 
indication of TKI is heterogenic. Recommendations would be useful for practice. 
 
